| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Hygric acid targets enzymes involved in amino acid metabolism and alkaloid biosynthesis. As an N-methylated proline derivative, it is a substrate for enzymes that modify amino acids and synthesize alkaloids. The compound may interact with proline transporters and proline-metabolizing enzymes. Its role in pyrrolizidine alkaloid biosynthesis suggests it targets enzymes involved in alkaloid formation. Further research is needed to identify its specific molecular targets and biological functions.
|
|---|---|
| ln Vitro |
In vitro studies of Hygric acid have focused on its role as a naturally occurring amino acid derivative and its involvement in alkaloid biosynthesis. The compound's metabolism by enzymes involved in amino acid modification has been characterized. Its use as a chemical intermediate for the synthesis of alkaloids and other bioactive compounds has been documented. These in vitro studies provide foundational data for understanding the compound's properties and its applications in natural product research and organic synthesis.
|
| ln Vivo |
In vivo studies of Hygric acid are limited, as the compound is primarily used as a research chemical. As a naturally occurring compound, it would be metabolized through standard amino acid pathways in vivo. Its role in alkaloid biosynthesis suggests it may be involved in plant metabolism. However, comprehensive in vivo studies specifically targeting Hygric acid are not well documented in the available literature. Further research is needed to fully characterize its in vivo pharmacokinetic and pharmacodynamic properties.
|
| Enzyme Assay |
In vitro enzyme assays for Hygric acid typically involve testing its activity as a substrate for enzymes involved in amino acid metabolism and alkaloid biosynthesis. Enzyme activity is measured by monitoring the conversion of the compound using chromatographic or spectrometric methods. The compound's ability to inhibit enzyme activity is assessed by measuring substrate conversion in the presence of varying concentrations of the compound. All assays are performed with appropriate controls and standardized protocols to ensure reproducibility of results.
|
| Cell Assay |
In vitro cell-based assays for Hygric acid involve culturing cells to evaluate its effects on amino acid metabolism. Cells are treated with varying concentrations of the compound and amino acid levels are measured using chromatographic methods. Cell viability is assessed using MTT or similar colorimetric assays. The compound's effects on cellular metabolism and gene expression are evaluated. All experiments are performed in triplicate with appropriate controls to ensure statistical reliability.
|
| Animal Protocol |
In vivo animal experiments for Hygric acid would be conducted to evaluate its metabolism and potential biological effects. Animals would be administered the compound and blood and tissue samples collected at various time points. The compound and its metabolites would be measured using appropriate analytical methods. Parameters assessed would include body weight, organ weights, and general health. Control groups receiving vehicle alone would be included for comparison. All procedures would comply with institutional animal care and use committee guidelines. Comprehensive in vivo studies are not well documented in the available literature.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Hygric acid reflect its nature as a small amino acid derivative. It has a molecular weight consistent with its formula C6H11NO2. As an amino acid derivative, it would be transported into cells via amino acid transporters and metabolized through standard amino acid pathways. The compound is expected to be excreted through the kidneys. Complete pharmacokinetic profiling including half-life, clearance, and bioavailability would require further systematic studies.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Hygric acid has been evaluated in the context of its use as a research chemical. As a naturally occurring amino acid derivative, it is expected to have a favorable safety profile at research concentrations. Proper handling procedures including use of personal protective equipment are recommended when working with pure compound. The compound is not approved for human therapeutic use and is intended for research purposes only. Long-term toxicity studies would be needed to fully establish its safety profile.
|
| References | |
| Additional Infomation |
N-Methylproline is a derivative of L-proline, obtained by replacing the amino hydrogen with a methyl group. It is a metabolite found in both plants and humans. It is an L-proline derivative and also a tertiary amine compound. It is a zwitterion tautomer of N-methylproline. Monomethylproline has been reported in cabbage (Brassica oleracea), pilosa (Trichilia claussenii), and other organisms with available data.
Hygric acid (N-Methyl-L-proline; CAS# 475-11-6) is an N-methylated amino acid derivative of L-proline with the molecular formula C6H11NO2. It is a naturally occurring compound found in various plants and is a constituent of the pyrrolizidine alkaloids. Hygric acid is used in research applications for studying amino acid metabolism, alkaloid biosynthesis, and as a chemical intermediate. It is intended for research use only and is not for human therapeutic use. |
| Molecular Formula |
C6H11NO2
|
|---|---|
| Molecular Weight |
129.16
|
| Exact Mass |
129.078
|
| CAS # |
475-11-6
|
| PubChem CID |
643474
|
| Appearance |
White to off-white solid
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
227.1±33.0 °C at 760 mmHg
|
| Melting Point |
114-116ºC(lit.)
|
| Flash Point |
91.1±25.4 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.498
|
| LogP |
-0.17
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
9
|
| Complexity |
124
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CN1CCC[C@H]1C(O)=O
|
| InChi Key |
CWLQUGTUXBXTLF-YFKPBYRVSA-N
|
| InChi Code |
InChI=1S/C6H11NO2/c1-7-4-2-3-5(7)6(8)9/h5H,2-4H2,1H3,(H,8,9)/t5-/m0/s1
|
| Chemical Name |
(2S)-1-methylpyrrolidine-2-carboxylic acid
|
| Synonyms |
N-Methyl-L-proline; Hygric acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (774.23 mM)
H2O: 100 mg/mL (774.23 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (19.36 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (19.36 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (19.36 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (774.23 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.7423 mL | 38.7117 mL | 77.4234 mL | |
| 5 mM | 1.5485 mL | 7.7423 mL | 15.4847 mL | |
| 10 mM | 0.7742 mL | 3.8712 mL | 7.7423 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
